AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 6-KAUG 72 min read$PPBT

PURPLE BIOTECH LTD. (PPBT): Financial results for Q2 2026

PURPLE BIOTECH LTD. (PPBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Purple Biotech Reports Second Quarter 2026 Financial Results New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240’s anti-tumor activity, favorable safety a

Original reporting
SEC EDGAR 6-K
Published Aug 7, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 7:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PPBT
Neutral
medium confidence
Mentioned
$PPBT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$PPBTNeutralMed
01

Why it matters

The earnings release provides fresh financial metrics and updates on a lead immunotherapy program, offering traders new data points for valuation.

02

Market read

Earnings release for a micro‑cap biotech; relevance primarily to specialty investors and sector analysts.

03

What to watch

Potential dilution from warrant revaluation and upcoming Phase 1 trial costs.

Relevance 7/10Novelty 7/10Timing: post‑market Aug 7 2026

Background

Purple Biotech (NASDAQ: PPBT) disclosed its Q2 2026 results, including preclinical data for its IM1240 candidate and cash position.

Company-level read

Ticker impact

$PPBTNeutralMedium confidence
Context

Quarterly earnings release with Q2 2026 financial results and cash runway update.

Expected impact

Modest upside potential pending market reaction to cash position and preclinical data.

Evidence & confidence

Micro‑cap biotech earnings often move on financing news; current data shows improved cash and preclinical progress, but no major revenue.

Market effects

Sector

Highlights continued R&D activity in immunotherapy biotech sector.

Regional

Limited to US and Israeli biotech investors.

Global

Minor, confined to niche oncology biotech space.

Counterpoint

What could challenge this read

Cash runway is short; without near‑term financing the stock may face pressure.

Key entities

  • company
    Purple Biotech Ltd.

    Clinical‑stage immunotherapy developer.

Read at source← All news

Related articles

SEP 2
$PPBTHigh

Why Is Purple Biotech Stock Gaining Wednesday? - Purple Biotech (NASDAQ:PPBT)

Purple Biotech (NASDAQ:PPBT) shares rose 22.89% premarket Wednesday after the U.S. Patent Office granted a Notice of Allowance for its tri-specific antibody constructs. The patent expands the company's IP for its CAPTN-3 platform, which aims to accelerate cancer treatment development. Preclinical data for lead candidate IM1240 showed anti-tumor activity, with human trials planned for 2027.

benzinga.com1 min
AUG 7
$PPBTMed

Purple Biotech Ltd.: Purple Biotech Reports Second Quarter 2026 Financial Results

Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2026 results and new preclinical data on its IM1240 tri-specific antibody. The company said IM1240 showed an 8-fold longer half-life and 16-fold higher exposure versus a non-capped variant, with reduced cytokines in toxicology work. Cash was $6.1 million at June 30, 2026, funding a runway to mid-2027. IM1240 is planned for clinical entry in 2027.

finanznachrichten.de6 min
JUN 11
$PPBTMed

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech presented preclinical EACR 2026 data on its CAPTN-3 program, IM1240. A non-GLP NHP toxicology study validated the CAPTN-3 masking strategy, reporting ~8-fold longer half-life and 16-fold higher exposure versus the non-capped variant IM1222, with markedly lower cytokine release. In patient-derived PD-1/chemo-resistant tumor samples, IM1240 showed anti-tumor activity requiring CD3 and NKG2A, and in NSCLC explants induced mature tertiary lymphoid structures. The company plans first-i

manilatimes.net5 min
SEP 22
$AZOHighAI 9/10

AutoZone Q4 Profit, Comps Rise; Sees Sales Growth In FY27

AutoZone reported Q4 earnings of $56.05 per share, up from $48.71 last year, with net sales rising 5.6% to $6.595 billion. Same-store sales grew 2.7%, with international sales up 10.7%. The company opened 175 new stores and expects sales growth in FY27. Shares gained 0.53% in pre-market trading.

rttnews.com2 min